Myriad Genetics (NASDAQ:MYGN) fiscal Q1 results:
Revenue: $186.3M (-7.9%); molecular diagnostic testing: $172.0M (-9.0%); hereditary cancer testing: $104.5M (-11.1%).
Results negatively impacted by deletion of historical hereditary cancer CPT codes.
Net loss: ($20.6M) (-999%); non-GAAP net income: $5.8M (-82.3%); loss/share:($0.28) (-999%); non-GAAP EPS: $0.08 (-81.4%).
Cash flow ops: $15.8M (+102.6%).
Fiscal Q2 guidance: Revenue: $210M – 212M; EPS: ($0.02) – 0.00; non-GAAP EPS: $0.30 – 0.32.
Fiscal 2020 guidance: Revenue: $800M – 810M; EPS: ($0.25 – 0.15); non-GAAP EPS: $1.00 – 1.10.
Shares down 35% premarket on modestly higher volume.
Previously: Myriad Genetics EPS misses by $0.23, misses on revenue (Nov. 4)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.